ClinicalTrials.gg
RecruitingNCT07042529OptEx-TAVIUpdated Jul 10, 2026

Optimized Expansion of the Implanted Transcatheter Aortic Valve

An interventional study of OptEx-TAVI and SoC-TAVI in Aortic Stenosis Disease and Valvular Heart Disease, sponsored by Ole De Backer. Recruiting at 17 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.

Primary conditionAortic Valve StenosisRegistry: Heart Valve DiseasesReclassifiedWhy we changed it
Registry
Heart Valve Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Aortic Valve Stenosis
Why
  1. The study's listed conditions name Aortic Valve Stenosis, a narrower term within Heart Valve Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Ole De Backer · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,010
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Aortic Valve Stenosis with a site in Belgium — 11 open to participants now, 14 under way, 1 of them phase 3. Aortic Valve Stenosis · Belgium.

Planned enrollment
4th of 27
1,010 · median 214
Started
2025
with 1 other
No phase
22 of 47
5 open now
Primary completion
2029-07
later than 11 of 13 live
Registered
47th of 47
by date

Among the 47 studies in Aortic Valve Stenosis with a site in Belgium, this one is the 4th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2025, is one of 22 with no phase, reaches primary completion later than 11 of the 13 other live ones, and was the 47th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

11 of the 47 studies in Aortic Valve Stenosis with a site in Belgium are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Aortic Valve Stenosis with a site in Belgium, or all of them as a file.
02

Study summary

Optimized Expansion of the implanted transcatheter aortic valve to reduce hypoattenuating leaflet thickening in non-atrial fibrillation patients undergoing transcatheter aortic valve implantation (TAVI): an international, multicentre, randomized controlled trial.

The objective is to evaluate whether TAVI with systematic optimized pre- and post-dilatation (optimized expansion (OptEx) TAVI strategy), compared to a standard of care (SoC) TAVI strategy, is superior in reducing hypoattenuating leaflet thickening as evaluated by cardiac computed tomography (CT) imaging at three months after TAVI.

The primary outcome is at least one thickened TAV leaflet involving ≥ 25% of the leaflet curvilinear dimension as assessed at cardiac CT at three months after TAVI.

Read the detailed description

A total of 1010 patients will be included in the OptEx-TAVI trial and randomised 1:1 to either :

  • SoC-TAVI (N = 505) or
  • OptEx-TAVI (N = 505)

All patients with indication for TAVI and eligible in relation to the study in- and exclusion criteria will be offered participation in the OptEx-TAVI trial.

Inclusion criteria:

  • Severe native aortic valve stenosis
  • Indication for TAVI
  • Ability to understand and to comply with the study protocol

Exclusion criteria:

  • Existing indication for oral anticoagulation (e.g., atrial fibrillation, venous thromboembolism, antiphospholipid syndrome, mechanical mitral valve)
  • Creatinine clearance \<15 mL/min (CKD-EPI formula) or on renal replacement therapy
  • Iodine contrast allergy or other condition that prohibits cardiac CT imaging

Baseline characteristics, medical history, procedural details, electrocardiogram, echocardiography and cardiac CT-scan parameters will be recorded by assessing medical charts and patient interview.

During the TAVI-procedure, patients will be treated according to randomisation to either SoC or OptEx

Planned post-procedural visits at:

  • Discharge: on-site - including transthoracic echocardiography (TTE)
  • 3 months visit (± 2 months): on-site - including TTE and cardiac CT scan
  • 1 year (± 3 months): on-site - including TTE and cardiac CT scan
  • 5 years (± 6 months): on-site - including TTE and cardiac positron emission tomography (PET)-CT scan
03

Conditions studied

  • Aortic Stenosis Disease
  • Valvular Heart Disease

Browse trials for

Keywords

  • Aortic stenosis
  • Cardiovascular
  • Transcatheter aortic valve
  • Transcatheter aortic valve implantation
  • Valvular heart disease
  • TAVI
04

In context

Aortic Valve Stenosis Reclassified

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

This study's planned enrollment of 1,010 is above the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.

Browse Aortic Valve Stenosis studies →

Lead sponsor

Ole De Backer is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Compared within Aortic Valve Stenosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Valve Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Severe native aortic valve stenosis
  • Indication for TAVI
  • Ability to understand and to comply with the study protocol

Exclusion criteria

Exclusion Criteria:

  • Existing indication for oral anticoagulation (e.g., atrial fibrillation, venous thromboembolism, antiphospholipid syndrome, mechanical mitral valve)
  • \<15 mL/min ( formula) or on renal replacement therapy
  • Iodine contrast allergy or other condition that prohibits cardiac CT imaging
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
1,010 participants (estimated)

Study arms

  • Active comparator
    SoC-TAVI

    Pre-dilatation and post-dialation optional, as per operator preference. The balloon size used for pre- or post-dilatation is left at the operator's discretion. Operators are only encouraged to post-dilate the implanted transcatheter aortic valve (TAV) in case of ≥ moderate paravalvular regurgitation or a suboptimal transvalvular gradient.

    Procedure: SoC-TAVI

  • Experimental
    OptEx-TAVI

    Systematic pre-dilatation and post-dilatation with an optimally-sized balloon

    Procedure: OptEx-TAVI

Interventions

  • ProcedureOptEx-TAVI

    During TAVI with either self-expanding or balloon-expandable TAVs: * Pre-dilatation: systematic pre-dilatation with an optimally-sized balloon. * Post-dilatation: systematic TAV post-dilatation with an optimally-sized balloon. Optimally-sized balloon: 1. The recommended balloon size used for pre- and post-dilatation is the perimeter-derived mean diameter of the native aortic annulus minus 1 mm and should never exceed the perimeter-derived mean diameter of the native aortic annulus. A smaller-sized balloon should be considered in case of severe left ventricular outflow tract calcium and/or severely calcified leaflets in combination with a shallow sinus of Valsalva. 2. In case of post-dilatation of the Evolut TAV (Medtronic, USA), the instructions for use (IFU) for post-dilatation of the Evolut valve should be respected. 3. Also, a balloon-expandable TAV has to be post-dilated with an optimally-sized balloon in case of randomization to the OptEx-TAVI arm.

  • ProcedureSoC-TAVI

    During TAVI with either self-expanding or balloon-expandable TAVs: Pre-dilatation: optional, as per operator preference and post-dilatation: optional, as per operator preference. Operators are only encouraged to post-dilate the implanted TAV in case of ≥ moderate paravalvular regurgitation or a suboptimal transvalvular gradient. The balloon size used for pre- or post-dilatation is left at the operator's discretion.

07

What researchers measure

Primary outcomes

  1. At least one TAV leaflet with HALT

    At least one TAV leaflet with hypoattenuated leaflet thickening (HALT) involving more than the base (≥ 25% of the leaflet curvilinear dimension) as assessed at cardiac CT-scan .

    Time frame: At three months after TAVI

Secondary outcomes

  1. HALT 50%

    At least one TAV leaflet with HALT involving ≥ 50% of the leaflet curvilinear dimension assessed by cardiac CT-scan

    Time frame: At 3 months/At 1 year

  2. HALT 25%

    The rate of TAV leaflets with HALT involving ≥ 25% of the leaflet curvilinear dimension assessed by cardiac CT-scan

    Time frame: At 3 months/At 1 year

  3. HALT 50%, multiple

    The rate of TAV leaflets with HALT involving ≥ 50% of the leaflet curvilinear dimension assessed by cardiac CT-scan

    Time frame: At 3 months/At 1 year

  4. Bioprosthetic leaflet micro-calcification target-to-background ratio

    Ratio of bioprosthetic micro-calcification activity assessed by PET CT- scan by 18F-NaF uptake originating from the valve leaflets observed on 3 orthogonal planes after co-registration of background PET activity with contrast CT angiography. Only for those patients alive at 5 years and volunteering to undergo a F-NaF PET-CT-scan

    Time frame: At 5 years

  5. Valve performance

    Intended performance of the valve (mean gradient \< 20 mmHg, peak velocity \< 3 m/s, Doppler velocity index ≥ 0.25, and less than moderate aortic regurgitation) by TTE as per VARC- 3 criteria

    Time frame: At 3 months/At 1 year

  6. structural valve deterioration

    Moderate or greater hemodynamic structural valve deterioration by TTE as per VARC-3 criteria. Only for those patients alive at 5 years and volunteering to undergo a F-NaF PET-CT-scan

    Time frame: At 5 years

  7. Bioprosthetic valve dysfunction (BVD)

    Severe bioprosthetic valve dysfunction (BVD) by TTE as per VARC-3 criteria. Only for those patients alive at 5 years and volunteering to undergo a F-NaF PET-CT-scan

    Time frame: At 5 years

  8. Bioprosthetic valve failure (BVF)

    As per VARC-3 criteria; Only for those patients alive at 5 years and volunteering to undergo a F-NaF PET-CT-scan

    Time frame: At 5 years

  9. Technical success

    As per VARC-3 criteria

    Time frame: Periprocedural

  10. Device success

    as per VARC-3 criteria

    Time frame: At 3 months

  11. Early safety

    As per VARC-3 criteria

    Time frame: At 3 months

  12. Clinical efficacy

    As per VARC-3 criteria

    Time frame: At 1 year

  13. Valve-related long-term clinical efficacy

    As per VARC-3 criteria; Only for those patients alive at 5 years and volunteering to undergo a F-NaF PET-CT-scan

    Time frame: At 5 years

  14. Freedom from mortality

    Freedom from mortality

    Time frame: Periprocedural, at 3 months and at 1 year

  15. Risk of cardiovascular mortality

    Risk of cardiovascular mortality. VARC-3 criteria

    Time frame: At 1 year

  16. Risk of non-cardiovascular mortality

    Risk of non-cardiovascular mortality. VARC-3 criteria

    Time frame: At 1 year

  17. Risk of acute kidney injury

    Risk of acute kidney injury stage 3 or 4. VARC-3 criteria

    Time frame: At 3 months

  18. Risk of bleeding

    Risk of VARC-3 type 2-4 bleeding

    Time frame: At 3 months, 1 year and 5 years (Only for those patients alive at 5 years and volunteering to undergo a F-NaF PET-CT-scan)

  19. Risk of stroke

    Risk of all stroke

    Time frame: At 3 months and 1 year

  20. Risk of thomboembolism

    Freedom from stroke or peripheral embolism (presumably valve-related, after ruling out other non-valve aetiologies). VARC-3 criteria.

    Time frame: At 5 years

  21. Rate of successful access

    Successful access, delivery of the device, and retrieval of the delivery system

    Time frame: Periprocedural

  22. Freedom from surgery or intervention

    Rate of freedom from surgery or intervention related to the device or to a major vascular or access-related, or cardiac structural complication

    Time frame: Periprocedural and at 3 months

  23. Risk of vascular complications

    Risk of major vascular, access-related, or cardiac structural complication, VARC-3 criteria.

    Time frame: At 3 months

  24. Risk of aortic prosthetic regurgitation

    Freedom from moderate or severe aortic regurgitation. VARC-3 criteria

    Time frame: At 3 months

  25. Risk of permanent pacemaker

    Risk of new permanent pacemaker due to procedure-related conduction abnormalities

    Time frame: At 3 months

  26. Risk of procedure or valve-related hospitalization

    Risk of hospitalization for procedure- or valve-related causes. VARC-3

    Time frame: At 1 year

08

Study locations

15 of 17 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jul 2029, 44 months after the start.

Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 44 months is close to that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2025
First posted
Jun 29, 2025
StartActual
Oct 5, 2025
Primary completionEst.
Jul 1, 2029
CompletionEst.
Jul 1, 2033
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07042529
Lead sponsor
Ole De Backer
Responsible party
Ole De Backer (Professor of Cardiology, Principal investigator, Rigshospitalet, Denmark) — Sponsor-investigator
First posted
Jun 29, 2025
Start date
Oct 5, 2025
Primary completion
Jul 1, 2029 (estimated)
Completion
Jul 1, 2033 (estimated)
Last update
Jul 10, 2026

Study contacts

Ole De Backer, MD, PhD, FESC
Contact
ole.de.backer@regionh.dk
+4535457086
Troels H Jørgensen, MD, PhD
Contact
troels.hoejsgaard.joergensen.01@regionh.dk
+4535450892
Ole De Backer, MD, PhD, FESC
principal investigator · The Heart Center, Rigshospitalet

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion